The HRH1 Knockout KYSE-30 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the KYSE-30 human esophageal squamous cell carcinoma line, featuring targeted disruption of the HRH1 gene. This gene-edited pool serves as a loss-of-function model for investigating histamine H1 receptor biology, avoiding artifacts associated with pharmacological inhibition. The polyclonal format preserves the inherent cellular heterogeneity of the knockout, providing a robust system for population-level analyses of HRH1-dependent phenotypes without reliance on single-cell clones.
The parental KYSE-30 cell line was established from a well-differentiated human esophageal squamous cell carcinoma and exhibits typical epithelial morphology and aggressive growth characteristics. As a widely employed model in esophageal cancer research, KYSE-30 recapitulates key oncogenic pathways relevant to tumor initiation and progression. Its origin from a clinically aggressive cancer type makes it particularly valuable for evaluating molecular mechanisms underlying esophageal squamous cell carcinoma, including aberrant proliferative and migratory behaviors often driven by receptor-mediated signaling.
HRH1 encodes the histamine H1 receptor, a Gq/11-coupled GPCR that transduces extracellular histamine signals into intracellular responses. Upon histamine binding, the receptor activates Gq/11 protein, which in turn stimulates phospholipase C (PLC) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). This leads to calcium mobilization from intracellular stores and protein kinase C (PKC) activation, culminating in the phosphorylation of ERK1/2 within the MAPK/ERK pathway and the induction of transcription factors such as NF-??B. Beta-arrestin and GPCR kinases additionally regulate receptor desensitization and internalization. Downstream, HRH1 signaling promotes the expression of IL-8 and other pro-inflammatory mediators, contributing to both inflammatory and oncogenic outcomes.
In the esophageal cancer context, HRH1-mediated signaling has been implicated in enhancing tumor cell proliferation, migration, and inflammatory microenvironment modulation. Knockout of HRH1 in KYSE-30 cells abrogates histamine-dependent MAPK/ERK and calcium responses, thereby impairing these malignant traits. This model thus enables precise dissection of HRH1 contributions to tumor biology, including its role in sustaining ERK-driven proliferation and NF-??B-mediated survival signals. It further facilitates investigation of crosstalk with parallel pathways such as PI3K/Akt, which is frequently hyperactivated in esophageal cancer, offering a platform to study signaling network perturbations upon receptor loss.
The HRH1 Knockout KYSE-30 Polyclonal Cells support a broad range of experimental applications, including functional assays such as calcium flux measurements, phospho-ERK analysis by western blotting, and RT-qPCR-based quantification of IL-8 and other target genes. These cells are amenable to histamine stimulation experiments, proliferation assays, and migration studies, enabling comprehensive characterization of histamine receptor biology in cancer. Additionally, they serve as a valuable tool for drug screening campaigns targeting HRH1 or its downstream effectors, as well as for allergy and inflammation research where H1 receptor antagonists are commonly employed. For detailed product information or technical support, please contact Ascent Research.
